- Home
- BNTC vs ALT Comparison
BNTC vs ALT Comparison
Compare BNTC & ALT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | BNTC | ALT |
|---|---|---|
| Founded | 1995 | 1997 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 411.4M | 415.3M |
| IPO Year | 2020 | 2005 |
Fundamental Metrics
Financial Performance| Metric | BNTC | ALT |
|---|---|---|
| Price | $10.91 | $3.20 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 6 |
| Target Price | ★ $27.67 | $17.67 |
| AVG Volume (30 Days) | 161.7K | ★ 3.1M |
| Earning Date | 05-13-2026 | 03-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 80.94 | 25.37 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $41,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 105.00 |
| 52 Week Low | $9.85 | $2.91 |
| 52 Week High | $17.15 | $7.73 |
Technical Indicators
Market Signals| Indicator | BNTC | ALT |
|---|---|---|
| Relative Strength Index (RSI) | 42.12 | 32.72 |
| Support Level | $10.10 | $2.91 |
| Resistance Level | $12.91 | $4.25 |
| Average True Range (ATR) | 0.71 | 0.18 |
| MACD | -0.10 | -0.02 |
| Stochastic Oscillator | 9.33 | 1.18 |
Price Performance
Historical ComparisonAbout BNTC Benitec Biopharma Inc.
Benitec Biopharma Inc is a clinical-stage biotechnology company focused on the advancement of novel genetic medicines. Its technology has the potential to provide a one-shot cure for a wide range of diseases that are addressed by strict ongoing treatment regimens or that have no effective treatment or only palliative care options. The Company is developing a silence and replace-based therapeutic (BB-301) for the treatment of Oculopharyngeal Muscular Dystrophy (OPMD), a chronic, life threatening genetic disorder.
About ALT Altimmune Inc.
Altimmune Inc is a clinical-stage biopharmaceutical company focused on developing treatments for obesity, metabolic diseases, and liver diseases. Its product candidate, pemvidutide (formerly known as ALT-801), is a novel, investigational, peptide-based GLP-1/glucagon dual receptor agonist. Pemvidutide is currently in clinical development for obesity and metabolic-associated steatohepatitis (MASH). The company also plans to pursue additional indications for pemvidutide that leverage the differentiated clinical profile of pemvidutide.